Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipeline
The company lowered full-year TTR sales guidance while reporting new Phase 2 starts, an FDA priority review for a partnered drug, and expanded AI collaborations.
SEC filing